Last reviewed · How we verify

Victrelis — Competitive Intelligence Brief

Victrelis (BOCEPREVIR) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis C Virus NS3/4A Protease Inhibitor. Area: Infectious Disease.

marketed Hepatitis C Virus NS3/4A Protease Inhibitor Chymase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Victrelis (BOCEPREVIR) — Merck & Co..

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Victrelis TARGET BOCEPREVIR Merck & Co. marketed Hepatitis C Virus NS3/4A Protease Inhibitor Chymase 2011-01-01
ABT-450/ritonavir ABT-450/ritonavir AbbVie (prior sponsor, Abbott) phase 3 Hepatitis C virus NS3/4A protease inhibitor HCV NS3/4A serine protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis C Virus NS3/4A Protease Inhibitor class)

  1. Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Victrelis — Competitive Intelligence Brief. https://druglandscape.com/ci/boceprevir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: